<DOC>
	<DOCNO>NCT00061373</DOCNO>
	<brief_summary>Ischemic stroke cause blood clot block flow blood brain damage brain cell . The clot , thrombus , make platelet fibrin . The medicine alteplase , also know tPA , standard drug use treat patient acute ischemic stroke . tPA attack fibrin portion blood clot . While intravenous ( iv ) tPA alone effective treat fibrin part clot approximately 30 % time , add commercially available drug eptifibatide treat clot component may improve effectiveness iv tPA therapy . This clinical trial determine acceptable dose eptifibatide combination aspirin , low molecular weight heparin tinzaparin , standard iv tPA therapy treatment acute ischemic stroke . Use clinical imaging base selection criterion hypothesize contribute treatment safety select patient low risk intracerebral hemorrhage . Also , selection evaluation patient magnetic resonance imaging ( MRI ) criteria result different risk benefit ratio select patient without MRI criterion lead different acceptable dose .</brief_summary>
	<brief_title>Combination Anti-Platelet Anti-Coagulation Treatment After Lysis Ischemic Stroke Trial ( CATALIST )</brief_title>
	<detailed_description>Study Population : All acute ischemic stroke patient treated standard iv tPA therapy within 3 hour stroke onset consider study participation . Patient select criterion minimize likelihood toxicity maximize likelihood response . These criterion include age 18-85 year old acute ischemic stroke moderate severity measure use National Institutes Health Stroke Scale Stroke Scale ( NIHSS ) less 22 leave hemisphere stroke , le 17 others ) clinical , radiological laboratory feature associate increase risk hemorrhage thrombolytic therapy . In MRI arm trial , patient must positive MRI evidence hypoperfusion correspond acute stroke symptom MRI evidence chronic micro-hemorrhages . Design : This open-label , dose escalation , safety proof principle clinical trial . All patient receive iv tPA therapy plus 81 mg aspirin orally ( 150 mg rectally ) 80 anti Xa IU/kg tinzaparin subcutaneously patient receive iv eptifibatide . Intravenous eptifibatide give dose-escalating manner . The five dose group eptifibatide 0 , 45 micro g/kg bolus , 90 micro g/kg bolus , 90 micro g/kg bolus plus 0.25 micro g/kg/min infusion 24 hour , 90 mg/kg bolus plus 0.5 micro g/kg/min infusion 24 hour . Investigational therapy begin early possible later 6 hour onset patient 's symptom . Two arm - MRI non-MRI arm - receive identical drug regime , dose escalation proceed independently either arm . A maximum 100 patient arm study , minimum 15 patient treat dose level . The outcome monitor Data Safety Monitoring Board ( DSMB ) . The DSMB authority stop recommend modification trial safety concern throughout trial occurrence severe adverse event ( SAE ) . Dose escalation one dose level next contingent DSMB approval . Outcome Measures : The primary safety endpoint determination toxicity one following : symptomatic intracranial hemorrhage ( ICH ) , major systemic hemorrhage , SAE relate study drug administration , within 72 hour start therapy . Adverse event monitor 30 day . The primary efficacy endpoint response MRI arm reperfusion measure perfusion weight imaging ( PWI ) 2 hour 24 hour start therapy substantial clinical recovery 24 hour non-MRI arm . Clinical outcome variable image variable record analyzed secondary exploratory analysis . If acceptable dose eptifibatide identify , dose eptifibatide investigate subsequent randomize placebo-controlled trial . MRI CT use radiological measure brain hemorrhage . The NIH Stroke Scale ( NIHSS ) use measure neurological worsening recovery . The NIHSS 15-item neurologic examination stroke scale use evaluate effect acute stroke level consciousness , language , neglect , visual-field loss , extra ocular movement , motor strength , ataxia , dysarthria , sensory loss . A trained observer rate patient 's ability answer question perform activity . Ratings 15 item score . Patients score 0 consider `` normal '' examination . Patients score 40 severe stroke symptom .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Tinzaparin</mesh_term>
	<mesh_term>Eptifibatide</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Diagnosis acute ischemic stroke plan start intravenous tPA . Acute ischemic stroke define measurable neurological deficit sudden onset , presume secondary focal cerebral ischemia . Stroke onset defined time patient last know without new clinical deficit . If stroke start sleep , stroke onset recorded time patient last known baseline . 2 . Disabling neurological deficit attributable acute ischemic stroke . 3 . NIHSS le equal 21 leave hemisphere stroke , NIHSS le equal 16 others . 4 . Age 1885 year , inclusive . 5 . Body weight great 50 kg . For MRI Arm : 6 . Screening MRI diagnostic focal cerebral ischemia correspond clinical deficit . The MRI evaluation must involve echo planar diffusion weight imaging , magnetic resonance angiography ( MRA ) , MRI perfusion . A normal appear MRA appropriate perfusion deficit eligible . An apparent stenosis occlusion MRA normal appear perfusion distally eligible . Poor quality uninterpretable MRA make patient ineligible . Patients normal appear diffusion weight image ( DWI ) eligible . 7 . Evidence perfusion weight image ( PWI ) MRI perfusion defect correspond acute stroke syndrome . The PWI assess relative mean transit time ( MTT ) image obtain prior start tPA therapy . EXCLUSION CRITERIA : 1 . Current participation another study investigational drug device within , prior participation present study , plan participation another therapeutic trial , prior final ( day 30 ) assessment trial . 2 . Symptoms suggestive subarachnoid hemorrhage , even CT MRI scan negative hemorrhage . 3 . Evidence acute myocardial infarction define least two follow three feature : 1 ) Chest pain suggestive cardiac ischemia ; 2 ) EKG finding ST elevation great 0.2 millivolt ( mV ) 2 contiguous lead , new onset leave bundle branch block , ST segment depression , Twave inversion ; 3 ) Elevated troponin I . 4 . Acute Pericarditis . 5 . Women know pregnant , lactate positive indeterminate pregnancy test . 6 . Patients would refuse blood transfusion medically indicate . 7 . Neurological deficit lead stupor coma ( NIHSS level consciousness [ item I ] score great equal 2 ) . 8 . High clinical suspicion septic embolus . 9 . Minor stroke nondisabling deficit rapidly improve neurological symptom . 10 . Baseline NIHSS great 21 leave hemisphere stroke great 16 others . 11 . Evidence acute chronic ICH head CT MRI . 12 . CT MRI evidence nonvascular cause neurological symptom . 13 . Signs mass effect cause shift midline structure CT MRI . 14 . Persistent hypertension systolic BP great 185 mmHg diastolic BP great 110 mmHg ( mean 3 consecutive arm cuff reading 2030 minute ) , control antihypertensive therapy require nitroprusside control . 15 . Anticipated need major surgery within 72 hour start study drug , carotid endarterectomy hip fracture repair . 16 . Any intracranial surgery , intraspinal surgery , serious head trauma ( head injury require hospitalization ) within past 3 month . 17 . Stroke within past 3 month . 18 . History ICH time past . 19 . Major trauma time stroke , hip fracture . 20 . Blood glucose great 200 milligram per diluent ( mg/dl ) . 21 . Presence history intracranial neoplasm ( except small meningioma ) arteriovenous malformation . 22 . Intracranial aneurysm , unless surgically endovascularly treat 3 month . 23 . Seizure onset stroke . 24 . Active internal bleeding . 25 . Major hemorrhage ( require transfusion , surgery hospitalization ) past 21 day . 26 . Major surgery , serious trauma , lumbar puncture , arterial puncture noncompressible site , biopsy parenchymal organ last 14 day . Major surgical procedure include limited following : major thoracic abdominopelvic surgery , neurosurgery , major limb surgery , carotid endarterectomy vascular surgery , organ transplantation . For nonlisted procedure , operate surgeon consult assess risk . 27 . Presumed documented history vasculitis . 28 . Known systemic bleeding platelet disorder , e.g. , von Willebrand 's disease , hemophilia , idiopathic thrombocytopenia purpura ( ITP ) , thrombotic thrombocytopenic purpura ( TTP ) , others . 29 . History heparin induce thrombocytopenia . 30 . Platelet count le 100,000 cells/microliter . 31 . Congenital acquire coagulopathy ( e.g . , secondary anticoagulant ) cause either follow : 1 . Activated partial thromboplastin time ( aPTT ) prolongation great 2 second upper limit normal local laboratory , except due isolated factor twelve ( XII ) deficiency . 2. International normalize ratio ( INR ) great equal 1.4 . Patients receive warfarin prior entry eligible provide INR le 1.4 warfarin safely discontinue least 48 hour . 32 . Life expectancy le 3 month . 33 . Other serious illness , e.g. , severe hepatic , cardiac , renal failure ; acute myocardial infarction ; complex disease may confound treatment assessment . 34 . Severe renal failure : Serum creatinine great 4.0 mg/dL dependency renal dialysis . 35 . Aspartate aminotransferase ( AST ) Alanine transaminase ( ALT ) great 3 time upper limit normal local laboratory . 36 . Treatment qualify stroke thrombolytic , antithrombotic glycoprotein inhibitor ( GPIIbIIIa ) outside protocol . 37 . Any administration thrombolytic drug prior 7 day . 38 . Treatment qualify stroke intravenous heparin unless aPTT prolongation great 2 second upper limit normal local laboratory prior study drug initiation . 39 . Treatment qualify stroke low molecular weight heparin heparinoid . 40 . Known hypersensitivity alteplase , aspirin , tinzaparin , eptifibatide , heparin , sulfites , benzyl alcohol , pork product . 41 . Anticoagulation ( evidence abnormal INR , aPTT , platelet count ) cause herbal therapy . 42 . Known history alcohol illicit drug use ( e.g . prior study drug administration ) FOR nonMRI arm ( item 4344 ) : 43 . Ischemic change screen CT great approximately one third territory middle cerebral artery territory qualitative assessment . 44 . Patients exclude screen MRI , except exclusion item 45 ( contraindication MRI ) item 46 ( PWI obtain uninterpretable ) item 51 ( MRI obtainable would put patient 3 hour time window tPA ) . FOR MRI arm ( item 4551 ) : 45 . Contraindication MRI scan . 46 . PWI obtain uninterpretable . 47 . No MTT defect correspond acute stroke deficit . 48 . Satellite DWI hyperintensity correspond hyperintensity T2 weight image FLAIR vascular territory different index stroke 49 . DWI abnormality large approximately one third territory middle cerebral artery territory qualitative assessment . 50 . Evidence multiple microbleeds gradient echo MRI ( GRE ) . 51 . Patient contraindication gadolinium contrast agent : prior adverse reaction gadolinium estimate glomerular filtration rate ( GFR ) less 60 milliliter per minute ( mL/min ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Alteplase</keyword>
	<keyword>Recombinant tissue plasminogen activator</keyword>
	<keyword>Reperfusion therapy</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Tinzaparin</keyword>
	<keyword>Eptifibatide</keyword>
	<keyword>Ischemic Stroke</keyword>
</DOC>